Pamela Aranda Lopez1, Mark Denny2, Ann-Kathrin Hartmann3, Astrid Alflen1, Hans Christian Probst3, Esther von Stebut4, Stefan Tenzer3, Hansjörg Schild3, Michael Stassen3, Peter Langguth2, Markus P Radsak5. 1. Third Department of Medicine, Johannes Gutenberg-University Medical Center, Langenbeckstr. 1, D-55131 Mainz, Germany. 2. Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg-University, Staudingerweg 5, 55099 Mainz, Germany. 3. Institute for Immunology, Johannes Gutenberg-University Medical Center, Langenbeckstr. 1, 55131 Mainz, Germany. 4. Department of Dermatology, Johannes Gutenberg-University Medical Center, 55131 Mainz, Germany. 5. Third Department of Medicine, Johannes Gutenberg-University Medical Center, Langenbeckstr. 1, D-55131 Mainz, Germany. Electronic address: radsak@uni-mainz.de.
Abstract
BACKGROUND: Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses. OBJECTIVE: Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination properties suited to induce high quality T cell responses for enhanced protection against infections. METHODS: TCI was performed by applying a MHC class I or II restricted epitope along with IMI-Sol or Aldara (each containing 5% Imiquimod) on the shaved dorsum of C57BL/6, IL-1R, Myd88, Tlr7 or Ccr7 deficient mice. T cell responses as well as DC migration upon TCI were subsequently analyzed by flow cytometry. To determine in vivo efficacy of TCI induced immune responses, CTL responses and frequency of peptide specific T cells were evaluated on day 8 or 35 post vaccination and protection in a lymphocytic choriomeningitis virus (LCMV) infection model was assessed. RESULTS: TCI with the imiquimod formulation IMI-Sol displayed equal skin penetration of imiquimod compared to Aldara, but elicited superior CD8+ as well as CD4+ T cell responses. The induction of T-cell responses induced by IMI-Sol TCI was dependent on the TLR7/MyD88 pathway and independent of IL-1R. IMI-Sol TCI activated skin-derived DCs in skin-draining lymph nodes more efficiently compared to Aldara leading to enhanced protection in a LCMV infection model. CONCLUSION: Our data demonstrate that IMI-Sol TCI can overcome current limitations of previous imiquimod based TCI approaches opening new perspectives for transcutaneous vaccination strategies and allowing the use of this enhanced cutaneous drug-delivery system to be tailored for the improved prevention and treatment of infectious diseases and cancers.
BACKGROUND: Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses. OBJECTIVE: Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination properties suited to induce high quality T cell responses for enhanced protection against infections. METHODS:TCI was performed by applying a MHC class I or II restricted epitope along with IMI-Sol or Aldara (each containing 5% Imiquimod) on the shaved dorsum of C57BL/6, IL-1R, Myd88, Tlr7 or Ccr7 deficient mice. T cell responses as well as DC migration upon TCI were subsequently analyzed by flow cytometry. To determine in vivo efficacy of TCI induced immune responses, CTL responses and frequency of peptide specific T cells were evaluated on day 8 or 35 post vaccination and protection in a lymphocytic choriomeningitis virus (LCMV) infection model was assessed. RESULTS:TCI with the imiquimod formulation IMI-Sol displayed equal skin penetration of imiquimod compared to Aldara, but elicited superior CD8+ as well as CD4+ T cell responses. The induction of T-cell responses induced by IMI-Sol TCI was dependent on the TLR7/MyD88 pathway and independent of IL-1R. IMI-Sol TCI activated skin-derived DCs in skin-draining lymph nodes more efficiently compared to Aldara leading to enhanced protection in a LCMV infection model. CONCLUSION: Our data demonstrate that IMI-Sol TCI can overcome current limitations of previous imiquimod based TCI approaches opening new perspectives for transcutaneous vaccination strategies and allowing the use of this enhanced cutaneous drug-delivery system to be tailored for the improved prevention and treatment of infectious diseases and cancers.
Authors: Max O Meneveau; Gina R Petroni; Elise P Salerno; Kevin T Lynch; Mark Smolkin; Elizabeth Woodson; Kimberly A Chianese-Bullock; Walter C Olson; Donna Deacon; James W Patterson; William W Grosh; Craig L Slingluff Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751
Authors: Federico Leonel Parra; Ayelen Tatiana Caimi; Maria Julia Altube; Diego Esteban Cargnelutti; Mónica Elba Vermeulen; Marcelo Alexandre de Farias; Rodrigo Villares Portugal; Maria Jose Morilla; Eder Lilia Romero Journal: Front Bioeng Biotechnol Date: 2018-11-06
Authors: Rayen Yanara Valdivia-Olivares; Maria Rodriguez-Fernandez; María Javiera Álvarez-Figueroa; Alexis M Kalergis; José Vicente González-Aramundiz Journal: Vaccines (Basel) Date: 2021-12-01
Authors: Julian Sohl; Ann-Kathrin Hartmann; Jennifer Hahlbrock; Joschka Bartneck; Michael Stassen; Matthias Klein; Matthias Bros; Stephan Grabbe; Federico Marini; Kevin Woods; Borhane Guezguez; Matthias Mack; Hansjörg Schild; Sabine Muth; Felix Melchior; Hans Christian Probst; Peter Langguth; Markus P Radsak Journal: NPJ Vaccines Date: 2022-09-24 Impact factor: 9.399